Hisense Pharmaceuticals: Report for the third quarter of 2024

SZSIOct 18 00:00 · Announcements

Haisen Pharmaceutical (001367.SZ) released its performance for the first three quarters, with a net income of 86.95 million yuan, a year-on-year increase of 20.89%.

Haisco Pharmaceutical (001367.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue...

Zhitong FinanceOct 17 19:50

Haisen Pharmaceutical (001367.SZ): The net income in the third quarter was 28.9097 million yuan, a year-on-year increase of 10.68%.

Glory October 17th, Heisen Pharmaceuticals (001367.SZ) released its third quarter report in 2024. In the third quarter of 2024, the company achieved a revenue of 0.109 billion yuan, a 21.83% increase from the same period last year; net profit attributable to shareholders of the listed company was 28.9097 million yuan, a 10.68% increase from the same period last year; net profit after deducting non-recurring gains and losses was 29.5743 million yuan, a 15.82% increase from the same period last year; basic earnings per share was 0.28 yuan per share.

Gelonghui FinanceOct 17 19:45

Express News | Haisen Pharmaceutical: plans to invest no less than 2 billion yuan in the construction of a new plant project (Phase I).

BreakingsOct 17 19:38

Haisco Pharmaceutical (001367.SZ) plans to grant 2.3 million restricted stocks at a grant price of 12.65 yuan per stock.

Hansen Pharmaceuticals (001367.SZ) disclosed the 2024 restricted stock incentive plan (draft), and the company plans to grant stocks to encourage...

Zhitong FinanceSep 12 21:16

Haisen Pharmaceuticals (001367.SZ): Currently, aluminum sucrose sulfate has obtained the CEP certificate issued by the European Directorate for the Quality of Medicines (EDQM) and has completed the US Drug Master File (DMF) registration (status A).

Heisen Pharmaceuticals (001367.SZ) held a performance briefing on September 10, 2024, discussing the latest developments of aluminum glycinate as a product category with strong competitive advantages for the company. The company stated that it has accumulated a wealth of technical research and development foundation in the long-term management practice of aluminum glycinate production. The synthesis process of aluminum glycinate is stable, environmentally friendly, and has low comprehensive cost. Currently, aluminum glycinate has obtained the CEP certificate issued by the European Directorate for the Quality of Medicines (EDQM) and has completed the US DMF filing (status is A status). Formulations from collaborative companies have been listed in the United States and sales have been growing rapidly. During the reporting period.

Gelonghui FinanceSep 10 18:40